The 36-month beta value for ADAP is at 2.40. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 1 as “sell.”
The public float for ADAP is 222.66M, and currently, shorts hold a 1.44% of that float. The average trading volume for ADAP on April 10, 2024 was 1.89M shares.
ADAP) stock’s latest price update
The stock price of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) has dropped by -5.84 compared to previous close of 1.37. Despite this, the company has seen a fall of -6.52% in its stock price over the last five trading days. Zacks Investment Research reported 2024-01-16 that Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.
ADAP’s Market Performance
Adaptimmune Therapeutics Plc ADR (ADAP) has seen a -6.52% fall in stock performance for the week, with a -16.23% decline in the past month and a 40.91% surge in the past quarter. The volatility ratio for the week is 6.05%, and the volatility levels for the past 30 days are at 9.73% for ADAP. The simple moving average for the past 20 days is -10.51% for ADAP’s stock, with a 45.55% simple moving average for the past 200 days.
Analysts’ Opinion of ADAP
Many brokerage firms have already submitted their reports for ADAP stocks, with Bryan Garnier repeating the rating for ADAP by listing it as a “Buy.” The predicted price for ADAP in the upcoming period, according to Bryan Garnier is $3.60 based on the research report published on March 24, 2023 of the previous year 2023.
Guggenheim, on the other hand, stated in their research note that they expect to see ADAP reach a price target of $5. The rating they have provided for ADAP stocks is “Buy” according to the report published on January 03rd, 2023.
Mizuho gave a rating of “Buy” to ADAP, setting the target price at $9 in the report published on November 09th of the previous year.
ADAP Trading at -6.78% from the 50-Day Moving Average
After a stumble in the market that brought ADAP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.07% of loss for the given period.
Volatility was left at 9.73%, however, over the last 30 days, the volatility rate increased by 6.05%, as shares sank -12.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +64.36% upper at present.
During the last 5 trading sessions, ADAP fell by -5.43%, which changed the moving average for the period of 200-days by +37.37% in comparison to the 20-day moving average, which settled at $1.4323. In addition, Adaptimmune Therapeutics Plc ADR saw 62.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADAP starting from Rawcliffe Adrian, who sale 30,080 shares at the price of $0.67 back on Jan 17 ’24. After this action, Rawcliffe Adrian now owns 44,848 shares of Adaptimmune Therapeutics Plc ADR, valued at $20,244 using the latest closing price.
Bertrand William C JR, the Chief Operating Officer of Adaptimmune Therapeutics Plc ADR, sale 18,908 shares at $0.67 during a trade that took place back on Jan 17 ’24, which means that Bertrand William C JR is holding 7,785 shares at $12,725 based on the most recent closing price.
Stock Fundamentals for ADAP
Current profitability levels for the company are sitting at:
- -2.38 for the present operating margin
- 0.84 for the gross margin
The net margin for Adaptimmune Therapeutics Plc ADR stands at -1.9. The total capital return value is set at -0.68. Equity return is now at value -187.96, with -37.31 for asset returns.
Based on Adaptimmune Therapeutics Plc ADR (ADAP), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -5.58. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is 28711.57.
Currently, EBITDA for the company is -127.91 million with net debt to EBITDA at 0.75. When we switch over and look at the enterprise to sales, we see a ratio of 2.91. The receivables turnover for the company is 1.28for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.85.
Conclusion
In conclusion, Adaptimmune Therapeutics Plc ADR (ADAP) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
